Literature DB >> 2426902

Calmodulin levels in psoriasis: the effect of treatment.

W F Tucker, S MacNeil, R A Dawson, S Tomlinson, S S Bleehen.   

Abstract

Epidermal calmodulin levels were measured in lesional and non-lesional skin in 20 psoriatics before and after treatment by a variety of established topical and systemic regimes. Pretreatment, 10 out of 20 patients showed elevated calmodulin levels in lesional epidermis. Clearance of psoriatic plaques was accompanied by a significant overall reduction (p less than 0.05) in epidermal calmodulin, irrespective of the treatment regime used. For the non-lesional epidermis, only 5 out of 17 patients initially showed elevated calmodulin levels and there was no significant reduction in those levels following treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2426902

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  4 in total

1.  Psoriasis.

Authors:  W F Tucker; S MacNeil
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-04

2.  Calmodulin-antagonism inhibits human keratinocyte proliferation.

Authors:  D Eichelberg; A Fuchs
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

3.  UVB-induced calmodulin increase in pig epidermis: analysis of the effect of the calmodulin antagonist, W-13.

Authors:  A Takagi; H Iizuka
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

4.  Effects of tiflucarbine as a dual protein kinase C/calmodulin antagonist on proliferation of human keratinocytes and release of reactive oxygen species from human leukocytes.

Authors:  L Hegemann; R Fruchtmann; B Bonnekoh; B H Schmidt; J Traber; G Mahrle; R Müller-Peddinghaus; L A van Rooijen
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.